Counterfeit activity has been a thorn in the side of pharma organizations for many years. The illicit production of counterfeit pharmaceuticals not only damages profits due to lost sales but can cause significant harm to brand reputation, especially if a patient were to suffer adverse effects from counterfeits.
Instead of simply tolerating counterfeit activity as a minimized risk, pharma organizations are increasingly investing in measures to guard their supply chain and prevent illicit activity. This report draws on expert insights from Servier and SICPA to identify the current weak points in pharma supply chains and offer advice for securing them.
Download this report to uncover:
- What the primary vulnerabilities are in pharma supply chains.
- The steps that pharma organizations can take to prevent illicit activity.
- What the wider implications of counterfeit activity are.
- Real-world examples of anti-counterfeiting in action.